Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TACTIVA CD4
- Development stage
- Preclinical
- Lead developer
- Tactiva Therapeutics
- Modality
- TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
TACTIVA CD4 is a preclinical-stage adoptive cell therapy developed by Tactiva Therapeutics for the treatment of solid tumors expressing the NY-ESO-1 cancer-testis antigen. The therapy utilizes hematopoietic stem cell (HSC)-derived CD4 T cells engineered to express a high-affinity T-cell receptor (TCR) specific for NY-ESO-1. Unlike traditional TCR-T therapies that focus primarily on mature CD8+ cytotoxic T cells, this approach leverages the unique properties of HSC-derived CD4+ cells to provide a long-term, self-renewing source of tumor-specific T cells. These cells are designed to provide sustained "cleanup" of remaining tumor cells and immune protection against cancer recurrence, complementing CD8-mediated tumor killing to achieve durable remissions in solid malignancies.
- Other names
- TACTIVA HSC-derived CD4 TCR-T cellTactiva NY-ESO-1 HSC-derived CD4 TCR-T cell therapyTACTIVA CD4 cell
02
Targets
HLA-DRB1 (Human leukocyte antigen DR beta chain)
Beyond the preview
Go deeper on TACTIVA CD4.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TACTIVA CD4.